Deliver Your News to the World

CybeRelease Announces (OTC: IMGM) Creates New Subsidiary


(, January 9, 2006 ) - Lake Harmony, PA - CybeRelease reports Imagin Molecular Corporation (OTCBB:IMGM), recently announced that the Company has formed a wholly owned subsidiary, Imagin Nuclear Partners (INP) that will operate PET business joint ventures. INP is a full-service joint venture molecular imaging partner that will own, operate and administer out-patient medical diagnostic imaging centers that utilizes PET and PET/CT (Computed Tomography) scanning equipment. PET is an advanced medical diagnostic imaging procedure used by physicians in the detection of certain cancers, coronary disease and neurological disorders including Alzheimer’s disease. INP is a cutting-edge company that specializes in using evidence based medicine driven by bioinformatics specifically positioned in the market to provide the maximal cost effective benefit to their joint venture partner community.

TheNewsWire Gainers are LightPath Technologies Inc. (Nasdaq: LPTH), Emisphere Technologies Inc. (Nasdaq: EMIS), Cerus Corp. (Nasdaq: CERS), BriteSmile Inc. (Nasdaq: BSML), Ceragon Networks Ltd. (Nasdaq: CRNT) and Idenix Pharmaceuticals Inc. (Nasdaq: IDIX).

TheNewsWire Decliners are Santarus Inc. (Nasdaq: SNTS), Spatialight Inc. (Nasdaq: HDTV), Cerus Corp. (Nasdaq: CERS), BriteSmile Inc. (Nasdaq: BSML), Ceragon Networks Ltd. (Nasdaq: CRNT) and Idenix Pharmaceuticals Inc. (Nasdaq: IDIX).

Imagin Molecular Corporation strategy is to become a leading investor and developer of PET Molecular Imaging businesses. Imagin will continue to add value to its portfolio through partnerships and acquisition of direct and ancillary PET businesses, and has expanded on its ability to finance and develop PET and PET related products and businesses throughout North American and International markets.

About Imagin Molecular Corporation:

Imagin Molecular Corporation strategy and focus dedicated to business opportunities in PET manufacturing and the diagnosis of cancer, heart disease and neurological diseases. Imagin Molecular Corporation has positioned the Company to be a factor in PET and ancillary molecular imaging businesses. Imagin Molecular Corporation is also the Parent of Cipher Multimedia a new Media Marketing and Distribution Solution Company that provides a Distribution Solution for publishers of digital content. Cipher Multimedia will develop marketing campaigns that will assist Imagin, Positron Corporation and other companies market their products and will continue to provide publishers a distribution solution for digital content.

About Positron Corporation:

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; The Heart Center of Niagara in Niagara Falls, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at

For further information please contact the Imagin Molecular Corporation at 630 371 5583

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $495.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.